Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:GRCE NASDAQ:NRXP NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.08-6.5%$2.88$0.78▼$4.98$146.27M1.773.08 million shs2.26 million shsGRCEGrace Therapeutics$2.33-2.5%$2.60$1.79▼$5.18$38.90M0.37256,019 shs170,487 shsNRXPNRx Pharmaceuticals$3.56-5.2%$3.45$1.62▼$5.05$136.22M2.141.38 million shs2.53 million shsSPRBSpruce Biosciences$51.87-0.5%$54.24$4.77▼$240.00$143.50M3.1157,408 shs30,833 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+5.02%+15.69%-66.13%-71.05%-57.09%GRCEGrace Therapeutics+5.75%+7.66%+8.64%-49.04%-18.43%NRXPNRx Pharmaceuticals-3.59%-5.29%+16.77%+56.02%+21.29%SPRBSpruce Biosciences-4.68%+10.70%+2.08%-25.48%+893.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.08-6.5%$2.88$0.78▼$4.98$146.27M1.773.08 million shs2.26 million shsGRCEGrace Therapeutics$2.33-2.5%$2.60$1.79▼$5.18$38.90M0.37256,019 shs170,487 shsNRXPNRx Pharmaceuticals$3.56-5.2%$3.45$1.62▼$5.05$136.22M2.141.38 million shs2.53 million shsSPRBSpruce Biosciences$51.87-0.5%$54.24$4.77▼$240.00$143.50M3.1157,408 shs30,833 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+5.02%+15.69%-66.13%-71.05%-57.09%GRCEGrace Therapeutics+5.75%+7.66%+8.64%-49.04%-18.43%NRXPNRx Pharmaceuticals-3.59%-5.29%+16.77%+56.02%+21.29%SPRBSpruce Biosciences-4.68%+10.70%+2.08%-25.48%+893.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.33Hold$6.25481.40% UpsideGRCEGrace Therapeutics 2.00Hold$6.00157.51% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25973.23% UpsideSPRBSpruce Biosciences 2.60Moderate Buy$163.00214.25% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, SPRB, NRXP, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026SPRBSpruce Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$123.006/16/2026SPRBSpruce Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$123.006/9/2026SPRBSpruce Biosciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$135.006/8/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/5/2026SPRBSpruce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026ADCTADC Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.006/4/2026ADCTADC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$6.00 ➝ $2.006/1/2026SPRBSpruce Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$200.00 ➝ $150.005/27/2026SPRBSpruce Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026SPRBSpruce Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$170.00 ➝ $150.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M1.68N/AN/A($1.50) per share-0.72GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ANRXPNRx Pharmaceuticals$1.23M104.98N/AN/A($0.54) per share-6.60SPRBSpruce Biosciences$4.91M29.05N/AN/A$39.72 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)GRCEGrace Therapeutics-$7.79M-$0.48N/AN/AN/AN/A-14.45%-13.58%8/11/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.04N/AN/AN/A-202.92%8/17/2026 (Estimated)SPRBSpruce Biosciences-$38.97M-$36.60N/AN/AN/AN/A-155.40%-101.67%8/13/2026 (Estimated)Latest GRCE, SPRB, NRXP, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/18/2026Q4 2026GRCEGrace Therapeutics-$0.24-$0.07+$0.17-$0.06$0.90 millionN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/13/2026Q1 2026SPRBSpruce Biosciences-$7.9340-$8.94-$1.0060-$8.94N/AN/A5/5/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.02GRCEGrace TherapeuticsN/A8.1014.96NRXPNRx PharmaceuticalsN/A0.290.29SPRBSpruce Biosciences0.164.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%GRCEGrace Therapeutics6.08%NRXPNRx Pharmaceuticals4.27%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%GRCEGrace Therapeutics11.10%NRXPNRx Pharmaceuticals6.40%SPRBSpruce Biosciences4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableGRCEGrace TherapeuticsN/A16.27 million14.47 millionN/ANRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableSPRBSpruce Biosciences202.75 million2.63 millionOptionableGRCE, SPRB, NRXP, and ADCT HeadlinesRecent News About These CompaniesSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate ControllerJune 15, 2026 | finance.yahoo.comSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumJune 8, 2026 | businesswire.comSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumMay 28, 2026 | businesswire.comSpruce Biosciences to Participate in Upcoming Conferences in JuneMay 27, 2026 | businesswire.comSpruce Biosciences Stockholders Approve Directors and Annual Say-on-PayMay 26, 2026 | tipranks.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | businesswire.comSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...May 4, 2026 | bakersfield.comBCraig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeApril 3, 2026 | zacks.comDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?March 18, 2026 | zacks.comSpruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossMarch 17, 2026 | insidermonkey.comSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMarch 9, 2026 | pharmiweb.comPSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 9, 2026 | businesswire.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | insidermonkey.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | msn.comSpruce Biosciences to Present at Upcoming Investor Conferences in MarchMarch 2, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRCE, SPRB, NRXP, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$1.08 -0.08 (-6.52%) Closing price 03:59 PM EasternExtended Trading$1.08 +0.00 (+0.37%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Grace Therapeutics NASDAQ:GRCE$2.33 -0.06 (-2.51%) Closing price 04:00 PM EasternExtended Trading$2.33 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.NRx Pharmaceuticals NASDAQ:NRXP$3.56 -0.20 (-5.21%) Closing price 03:59 PM EasternExtended Trading$3.59 +0.03 (+0.84%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Spruce Biosciences NASDAQ:SPRB$51.87 -0.27 (-0.52%) Closing price 04:00 PM EasternExtended Trading$51.16 -0.70 (-1.36%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
